- Home
- EYPT vs PSNL Comparison
EYPT vs PSNL Comparison
Compare EYPT & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | PSNL |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EYPT | PSNL |
|---|---|---|
| Price | $5.45 | $13.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $31.80 | $12.20 |
| AVG Volume (30 Days) | ★ 3.8M | 3.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | $3,115.57 | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.95 | $4.45 |
| 52 Week High | $19.11 | $16.39 |
Technical Indicators
Market Signals| Indicator | EYPT | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 27.72 | 55.27 |
| Support Level | N/A | $6.89 |
| Resistance Level | $15.31 | $14.81 |
| Average True Range (ATR) | 0.93 | 0.57 |
| MACD | -0.67 | 0.02 |
| Stochastic Oscillator | 13.83 | 70.40 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.